Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 7/20 | 0.34 |
| ▸ | CSF1R | P07333 | 6/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | BRD2 | P25440 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4930184 | 0.88 | PDE4B (0.47) | PDE4BSYKCSF1RBRD4CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL4929976 | 0.84 | PDE4B (0.51) | PDE4BCSF1RBRD4CYP3A4CYP2C9 | |
| Trifluoroacetic Acid SCHEMBL4924249 | 0.84 | PDE4B (0.48) | PDE4BCYP3A4CYP2C9CYP2C19 | |
| Trifluoroacetic Acid SCHEMBL4921100 | 0.84 | PDE4B (0.53) | PDE4BKCNH2CSF1RBRD4CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL4927212 | 0.82 | PDE4B (0.46) | PDE4B | |
| SCHEMBL4924230 | 0.82 | PDE4B (0.57) | PDE4BCSF1RBRD4CYP3A4CYP2C9 | |
| SCHEMBL4928534 | 0.82 | PDE4B (0.59) | PDE4BCSF1RBRD4CYP3A4CYP2C9 | |
| Trifluoroacetic Acid SCHEMBL4928901 | 0.82 | PDE4B (0.48) | PDE4BCSF1RBRD4CYP3A4CYP2C9 | |
| SCHEMBL4930021 | 0.81 | PDE4B (0.51) | PDE4BKCNH2SYKCSF1RBRD4 | |
| Trifluoroacetic Acid SCHEMBL4920764 | 0.81 | PDE4B (0.49) | PDE4BKCNH2CSF1RCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146563-A1 | 1,7-Naphthyridines as Pde4 Inhibitors | GLAXO GROUP LIMITED | 2008-06-19 | — | — | US | claimed |
| US-20080146563-A1 | 1,7-Naphthyridines as Pde4 Inhibitors | GLAXO GROUP LIMITED | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146563-A1 | 1,7-Naphthyridines as Pde4 Inhibitors | PDE4A, PDE3B, PDE4B | PDE4B 3/4885KCNH2 594/4885SYK 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.